Published in Curr Med Res Opin on September 01, 2005
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health (2008) 0.99
Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag (2006) 0.83
Retracted Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother (2011) 0.83
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric (2012) 0.80
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health (2007) 0.79
Recommendations for raloxifene use in daily clinical practice in the Swiss setting. Eur Spine J (2012) 0.79
Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Womens Health (2010) 0.79
Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab (2012) 0.78
Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J (2009) 0.78
Assessing risks and benefits of genistein and soy. Environ Health Perspect (2006) 0.78
The effects of raloxifene treatment on oxidative status in brain tissues and learning process of ovariectomized rats. Iran J Reprod Med (2011) 0.77
Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nat Rev Cardiol (2015) 0.77
The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis. Asian Spine J (2015) 0.75
Selective Estrogen Receptor Modulators Suppress Hif1α Protein Accumulation in Mouse Osteoclasts. PLoS One (2016) 0.75
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause (2015) 0.75
Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan. Osteoporos Int (2014) 0.75
The Tissue-Selective Estrogen Complex: A Review of Current Evidence. Rheumatol Ther (2015) 0.75
Effect of ormeloxifene, a nonsteroidal once-a-week oral contraceptive, on systemic hemodynamics in adult female rats. J Pharmacol Pharmacother (2011) 0.75
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation (2009) 2.41
Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res (2006) 1.65
Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin (2006) 1.04
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke (2008) 0.97
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat (2012) 0.96
The impact of stress urinary incontinence on sexual activity in women. Cleve Clin J Med (2005) 0.92
Partial-mouth assessment of periodontal disease in an adult population of the United States. J Periodontol (2003) 0.90
Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J (2004) 0.88
Efficacy of two 65% permethrin spot-on formulations against induced infestations of Ctenocephalides felis (Insecta: Siphonaptera) and Amblyomma americanum (Acari: Ixodidae) on beagles. Vet Ther (2003) 0.87
Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin (2014) 0.86
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis (2013) 0.86
Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast Cancer Res Treat (2006) 0.86
Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther (2004) 0.84
Raloxifene use in clinical practice: efficacy and safety. Menopause (2009) 0.84
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol (2006) 0.84
Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Psychol Med (2007) 0.83
Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin (2008) 0.83
Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Curr Med Res Opin (2008) 0.81
Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci (2013) 0.81
Association of leptin with poor ovarian stimulation during in vitro fertilization. J Reprod Med (2005) 0.80
Repellency and efficacy of a 65% permethrin spot-on formulation for dogs against Aedes aegypti (Diptera: Culicidae) mosquitoes. Vet Ther (2003) 0.79
Estrogen increases inducible nitric oxide synthase gene expression. Am J Obstet Gynecol (2003) 0.79
Patient characteristics and utilization of breast cancer screening or diagnostic procedures prior to initiation of raloxifene, bisphosphonates and calcitonin. Curr Med Res Opin (2010) 0.78
Leukocyte response to dental plaque accumulation: a risk factor for heart disease? Arch Intern Med (2005) 0.78
Carotid artery intima-media thickness after raloxifene treatment. J Womens Health (Larchmt) (2007) 0.78
Compliance with mammography and bone mineral density screening in women at least 50 years old. Menopause (2011) 0.78
Differential effects of selective estrogen receptor modulators and estrogens on mammary blood flow in the ovine. Am J Obstet Gynecol (2002) 0.77
Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause (2005) 0.77
Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism (2005) 0.76
Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration. Clin Breast Cancer (2009) 0.76
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause (2012) 0.75
Review of comparative effectiveness of treatments to prevent fractures. Ann Intern Med (2008) 0.75
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis. J Drugs Dermatol (2020) 0.75
Periodontal assessment by right- and left-handed examiners: is there a difference? J Periodontol (2006) 0.75
Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep. Am J Physiol Heart Circ Physiol (2006) 0.75